Function Oncology
Function Oncology is a biotechnology company that leverages a CRISPR-enabled platform to understand cancer biology and develop the next generation of targeted cancer therapies. The company uses CRISPR gene editing technology to conduct functional genomic screens that identify cancer dependencies and therapeutic targets, enabling the discovery of novel drug candidates that address specific genetic vulnerabilities in…
Funding snapshot
About
Function Oncology is a biotechnology company that leverages a CRISPR-enabled platform to understand cancer biology and develop the next generation of targeted cancer therapies. The company uses CRISPR gene editing technology to conduct functional genomic screens that identify cancer dependencies and therapeutic targets, enabling the discovery of novel drug candidates that address specific genetic vulnerabilities in tumor cells. By systematically mapping which genes are essential for cancer cell survival across different tumor types, Function Oncology aims to develop precision oncology treatments that are more effective and less toxic than conventional chemotherapy. The platform integrates high-throughput CRISPR screening with computational biology to prioritize targets and accelerate drug development. Founded in 2018 and headquartered in San Diego, California, the company has raised $28 million in Series A funding from investors including Andreessen Horowitz, Casdin Capital, Alexandria, S32, and Section 32.
Business model
Life Sciences Tech > Research & Development > Drug Discovery > Genomics > Drug Development > Cancer,
Oncology > In-Vitro Diagnostic Tests > Diversified > Precision Medicine,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Precision Medicine > Oncology
Team background
Company Wise > Google,
College Wise > University of Cambridge, Cornell University
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.